Loading...
•
Dec 31, 2021
Guardant Health Q4 2021 Earnings Report
Guardant Health experienced revenue growth and advancements in clinical testing and screening programs.
Key Takeaways
Guardant Health reported a 38% increase in revenue for Q4 2021, driven by growth in clinical testing and development services. The company also highlighted progress in its ECLIPSE and SHIELD studies and finalized a settlement with Foundation Medicine.
Revenue reached $108 million, a 38% increase compared to Q4 2020.
Clinical test volume increased by 48% and biopharma test volume increased by 36% year-over-year.
ECLIPSE pivotal study for Guardant Shield blood test reached enrollment of 12,750 patients.
First patient enrolled in SHIELD study to validate blood-based assay in lung cancer screening.
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Guardant Health expects full year 2022 revenue to be in the range of $460 million to $470 million, representing 23% to 26% growth over full year 2021.